 |
| |
| |
 |
| Accelerated Holding Corp. |
OBP IV |
Hackensack, NJ
Accelerated Holding creates and efficiently develops new enterprises within the medical technology arena, focusing on the cardiovascular market, by leveraging its infrastructure and the know-how of involved clinicians and researchers.
|
|
 |
| |
 |
| Affinium Pharmaceuticals, Ltd. |
OBP V |
Toronto, Ontario, Canada
www.afnm.com
Affinium is a pharmaceutical company focused on the clinical development of antibacterials. Their lead development program encompasses a potent, orally available, novel antibiotic class for the treatment of antibiotic resistant staphylococcal infections.
|
|
|
| |
 |
| Applied Spine Technologies, Inc. |
OBP IV |
New Haven, CT
www.appliedspine.com
Applied Spine Technologies is a spine company focused on developing implantable dynamic stabilization systems for the treatment of chronic back pain.
|
|
|
| |
 |
| Astex Therapeutics Ltd. |
OBP II, III |
Cambridge, UK
www.astex-therapeutics.com
Astex is a drug discovery company applying novel protein structure-based technologies for the discovery of small molecule therapeutics.
|
|
|
| |
 |
| AVEO Pharmaceuticals, Inc. |
OBP IV |
Cambridge, MA
www.aveopharma.com
AVEO is a cancer therapeutics discovery company using in vivo tumor models and focusing on tumor maintenance genes.
|
|
|
| |
 |
| BioProcessors Corporation |
OBP IV |
Woburn, MA
www.bioprocessors.com
BioProcessors is a start-up company that is developing an automated, parallel,
miniaturized platform to enable the growth, culture, study and analysis of living cells.
|
|
|
| |
 |
| BrainCells Inc. |
OBP IV |
La Jolla, CA
www.braincellsinc.com
BrainCells Inc. is a neurogenesis-based drug discovery and development company targeting novel therapies for disorders of mood and anxiety.
|
|
|
| |
 |
| Cambrios Technologies Corp. |
OBP IV |
Sunnyvale, CA
www.cambrios.com
Cambrios Technologies Corp. applies peptide affinity and biological patterning technologies to commercially important materials in semiconductor and other industries. Cambrios’ technologies enable rapid and low cost formation of patterned thin films of essentially any material, and are of particular use in large area electronic applications such as flat panel displays.
|
|
|
| |
 |
| CardioFocus, Inc. |
OBP III |
Marlborough, MA
www.cardiofocus.com
CardioFocus develops laser-based technology for the treatment of the underlying causes of atrial fibrillation.
|
|
|
| |
 |
| Ceres, Inc. |
OBP II |
Thousand Oaks, CA
www.ceres.net
Ceres is a plant genomics company identifying key genes determining seed size, quantity, and yield amounts, as well as pesticide and herbicide resistance.
|
|
|
| |
 |
| CGI Pharmaceuticals Inc. |
OBP V |
Branford, CT
www.cellulargenomics.com
CGI Pharmaceuticals is dedicated to the discovery and development of small molecule kinase inhibitors for autoimmune/allergic/inflammatory disease (AAID) indications and oncology/angiogenesis.
|
|
|
| |
 |
| CircuLite, Inc. |
OBP IV |
Saddle Brook, NJ and Aachen, Germany
www.circulite.net
CircuLite develops superficially implanted ventricular assist devices to treat congestive heart failure that align with the operating skills of the interventional cardiologist.
|
|
|
| |
 |
| Claros Diagnostics, Inc. |
OBP V |
Woburn, MA
www.clarosdx.com
Claros Diagnostics is developing point-of-care medical diagnostic instruments which allow laboratory-quality testing to be performed directly by physicians and healthcare professionals. The company’s initial product is an immunoassay system providing urologists with quantitative blood-based results in minutes.
|
|
|
| |
 |
| Coherex Medical, Inc. |
OBP V |
www.coherex.com
Salt Lake City, UT
Coherex Medical is developing safer technologies such as a minimally invasive implant to close a heart defect called a patent foramen ovale, or PFO, and to induce tissue growth. PFO has been linked to at least two medical conditions that may benefit greatly from closure: cryptogenic stroke and migraine.
|
|
|
| |
 |
| Concentric Medical, Inc. |
OBP IV |
Mountain View, CA
www.concentric-medical.com
Concentric Medical is building a franchise in neurovascular intervention by developing new device-based
treatments for ischemic and hemorrhagic stroke. Concentric’s leading product, the proprietary MERCI™ System
has the potential of revolutionizing ischemic stroke intervention by providing a simple and innovative
mechanical method of removing thrombus to restore blood flow.
|
|
|
| |
 |
| Decision Biomarkers, Inc. |
OBP IV |
Waltham, MA
www.decisionbiomarkers.com
Decision Biomarkers is developing a multiplexed immunoassay technology to simultaneously analyze 20-40 different protein biomarkers.
|
|
|
| |
 |
| Dicerna Pharmaceuticals, Inc. |
OBP V |
Boston, MA
www.dicerna.com
Dicerna Pharmaceuticals is developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism.
|
|
|
| |
 |
| Dynogen Pharmaceuticals, Inc. |
OBP IV |
Waltham, MA
www.dynogen.com
Dynogen is a clinical-stage company developing a portfolio of more effective treatments for gastrointestinal and genitourinary disorders. The company is focused on capturing value in attractive and untapped markets in disease areas that severely impair a patient’s quality of life, such as irritable bowel syndrome, gastroesophageal reflux disease and overactive bladder. The company leverages its development expertise to identify promising clinical compounds and rapidly advance them towards registration.
|
|
|
| |
 |
| Elixir Pharmaceuticals, Inc. |
OBP III |
Cambridge, MA
www.elixirpharm.com
Elixir is a drug discovery company developing therapeutics to treat age-related diseases, with a focus on metabolic diseases such as diabetes and obesity.
|
|
|
| |
 |
| Enanta Pharmaceuticals, Inc. |
OBP III |
Watertown, MA
www.enanta.com
Enanta Pharmaceuticals is using its cutting-edge chemistry technology and drug
discovery capabilities to create best in class small molecule drugs. The company is initially
focused on building a pipeline of first generation bridged bicyclic macrolide and ketolide
antibiotics to combat bacterial resistance in the treatment of respiratory tract infections (RTI)
and hospital borne diseases.
|
|
|
| |
 |
| Ensemble Discovery, Inc. |
OBP IV |
Cambridge, MA
www.ensemblediscovery.com
Utilizes its novel DNA Programmed Chemistry to direct synthetic organic chemical reactions in order to overcome the limitations - such as speed, expense and structural diversity - of methods currently used to generate novel small molecules.
|
|
|
| |
 |
| Entomed, S.A. |
OBP II |
Illkirch, France
Entomed designs and develops novel antibiotics derived from insects.
|
|
|
| |
 |
| FlowMedica, Inc. |
OBP IV |
Fremont, CA
www.flowmedica.com
FlowMedica, Inc. develops a renal infusion catheter for selective delivery of pharmaceuticals to the renal circulation. Initially, the device is intended for two clinical applications: treatment of acute renal failure in patients suffering from congestive heart failure, and prevention of radiocontrast nephropathy in patients undergoing interventional cardiology procedures.
|
|
|
| |
 |
| HydroCision, Inc. |
OBP III |
Billerica, MA
www.hydrocision.com
HydroCision develops minimally invasive surgical products using a fluid jet technology for cutting and ablating tissue with applications in orthopedics, urology, and gynecology.
|
|
|
| |
 |
| ImpactRx, Inc. |
OBP III |
Mt. Laurel, NJ
www.impactrx.com
ImpactRx is a promotion research company providing detailed analysis of the effects of pharmaceutical company promotion efforts. ImpactRx builds
exclusive networks of high-prescribing physicians who provide real-time diagnosis, drug and promotion information.
|
|
|
| |
 |
| Intechra Inc. |
OBP V |
Jackson, MS
www.intechra.com
Intechra is the leading information technology asset disposition company. Intechra provides data security, liability indemnification and value recovery for large corporations (healthcare, financial, insurance, government) that are disposing of old servers, hard-drives, PCs and other electronic assets.
|
|
|
| |
 |
| IntraPace, Inc. |
OBP IV |
Menlo Park, Ca
www.intrapace.com
IntraPace is developing an endoscopically delivered gastric pacemaker for obesity treatment.
|
|
|
| |
|
| Laboratory Partners, Inc. |
OBP IV |
Palo Alto, CA
Laboratory Partners is a provider of clinical diagnostic testing services for healthcare providers, both hospitals and private practices, effectively competing in local markets against a range of national and other local clinical diagnostic laboratories.
|
|
|
| |
 |
| Luca Technologies |
OBP V |
Golden, CO
www.lucatechnologies.com
Luca Technologies is developing a novel, long-term, biotechnology-driven solution to rising U.S. dependence on foreign energy sources.
|
|
|
| |
 |
| Message Pharmaceuticals, Inc. |
OBP II |
Malvern, PA
Message Pharmaceuticals, Inc. is leveraging its proprietary platform technology in developing new classes of drugs that mimic RNA binding proteins to treat all major disease categories.
|
|
|
| |
 |
| Mitralign, Inc. |
OBP IV |
Tewksbury, MA
www.mitralign.com
Develops a novel percutaneous transcatheter medical device for the treatment of mitral valve regurgitation, a disorder than can either cause or be exacerbated by congestive heart failure.
|
|
|
| |
 |
| nFocus Neuromedical, Inc. |
OBP V |
Menlo Park, CA
www.nfocusneuro.com
nFocus develops innovative next generation neurovascular devices for the treatment of wide neck aneurysms and large arterio-venous malformations (AVMs).
|
|
|
| |
 |
| NotifyMD, Inc. |
OBP I |
(Formerly Ring Medical)
Nashville, TN
www.notifymd.com
NotifyMD is a physician communications portal that ensures the discrete exchange of
information between patients and physicians via traditional telephone answering services
using live operators at nine medical call centers and the most sophisticated electronic media such as the Internet, wireless communications devices and unified messaging.
|
|
|
| |
 |
| Pathway Medical Technologies, Inc. |
OBP V |
Redmond, WA
www.pathwaymedical.com
Pathway is developing catheter technology to remove and aspirate thrombus in coronary arteries, bypass grafts and other arteries.
|
|
|
| |
 |
| Radius |
OBP IV |
Cambridge, MA
www.radiuspharm.com
Radius is a privately held company that is a leader in the discovery and development of a new generation of drug therapies for osteoporosis and women’s health.
|
|
|
| |
 |
| Rib-X Pharmaceuticals, Inc. |
OBP IV |
New Haven, CT
www.rib-x.com
Rib-X uses structure-based drug design to discover new
classes of antibiotics based on the high-resolution crystal structure of the 50s ribosomal subunit.
|
|
|
| |
 |
| SmartPill Corporation |
OBP V |
Buffalo, NY
www.smartpillcorp.com
The SmartPill Corporation is a developer and manufacturer of ingestible, capsule-based medical devices that aid in the diagnosis, definition and therapeutic intervention of gastrointestinal disorders and diseases. Their flagship product, the SmartPill pH.p., is an ingestible capsule that measures acidity, pressure and temperature within the entire GI tract to diagnose GI motility disorders. This ‘pill’ is currently FDA approved to diagnose certain GI conditions.
|
|
|
| |
 |
| Solstice Neurosciences, Inc. |
OBP IV |
Malvern, PA and South San Francisco, CA
www.solsticeneuro.com
Solstice Neurosciences is a specialty biopharmaceutical company focused on the neurology market. Solstice's first product, Myobloc (Botulinum Toxin Type B), is currently approved in the USA and Europe for use in cervical dystonia.
|
|
|
| |
 |
| superDimension, Ltd. |
OBP IV |
Herzliya, Israel and Plymouth, MN
www.superdimension.com
superDimension has a minimally invasive technology platform for interventional pulmonology, providing clinicians with 3-D visualization. This enables physicians to direct a variety of instruments through the lungs.
|
|
|
| |
 |
| Tragara Pharmaceuticals, Inc. |
OBP V |
San Diego, CA
www.tragarapharma.com
Tragara Pharmaceuticals, Inc. is a clinical-stage oncology specialty pharmaceuticals company focusing on the development of therapeutics in cancer and inflammation related disorders.
|
|
|
| |
 |
| VaxInnate Corporation |
OBP IV |
Cranbury, NJ and New Haven, CT
www.vaxinnate.com
VaxInnate is developing prophylactic and therapeutic vaccines; technology based on research and discoveries of leading scientists from Yale University.
|
|
|
| |
 |
| Xanthus Pharmaceuticals, Inc. |
OBP IV |
Cambridge, MA
www.xanthus.com
Xanthus focuses on oncology development and aims to commercialize drugs with a test enabling personalized dosing of chemotherapeutic agents.
|
|
|
| |
 |
| Xencor, Inc. |
OBP V |
Monrovia, CA
www.xencor.com
Xencor is a later-stage company that has successfully developed a protein engineering technology and has used that technology to develop a clinical pipeline. Xencor has partnered with leading biotech companies, including Genentech and Eli Lilly and is designing next-generation protein drug candidates with improved selectivity, efficacy and safety.
|
|
|
| |
 |
| ZettaCore, Inc. |
OBP IV |
Englewood, CO
www.zettacore.com
ZettaCore applies life science technology to the semiconductor manufacturing process by utilizing porphyrin bio-molecules to create molecular memory for electronic storage devices.
|
|
|
| |
